Home : Medical Devices : Gadolinium & Nephrogenic Systemic Fibrosis (NSF) : Wikipedia : Nephrogenic systemic fibrosis

Wikipedia - Nephrogenic systemic fibrosis

Nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy is a rare and serious syndrome that involves fibrosis of skin, joints, eyes, and internal organs. Its cause is not fully understood, but it seems to be associated with exposure to gadolinium (which is frequently used as a contrast substance for MRIs) in patients with severe kidney failure. It does not have a genetic basis.

In NSF, patients develop large areas of hardened skin with fibrotic nodules and plaques. Flexion contractures with an accompanying limitation of range of motion can also occur. NSF resembles scleromyxedema at the histologic (microscopic) level; it shows a proliferation of dermal fibroblasts and dendritic cells, thickened collagen bundles, increased elastic fibers, and deposits of mucin. [1]

Most patients with NSF have undergone hemodialysis for renal failure, some have never undergone dialysis and others have received only peritoneal dialysis. Many patients have taken immunosuppressive medications and have other diseases, such as hepatitis C. Four of the seven gadolinium contrast agents approved by the U.S. Food and Drug Administration have been principally implicated in NSF, including Omniscan, Multihance, Magnevist, and OptiMARK.

The first cases of NSF were identified in 1997,[2] but NSF was first described as an independent disease entity in 2000.[3] While skin involvement is on the foreground, the process may involve any organ and resembles diffuse scleroderma or systemic sclerosis. [4] In 2006, the link between NSF and gadolinium-containing contrast agents was made.[5][6][7] As a result, gadolinium-containing contrast is now considered contraindicated in patients with an estimated glomerular filtration rate (a measure of renal function) under 60 and especially under 30 ml/mn.[8]

The European Medicines Agency has classified the gadolinium-containing contrast agents in three groups:[9]

  • Least likely (safest) to release free gadolinium ions Gd3+ in the body have a cyclical structure: Dotarem, Gadovist and ProHance
  • Intermediate have an ionic linear structure: Magnevist, MultiHance, Primovist (Eovist in the U.S.) and Vasovist
  • Most likely to release Gd3+ have a linear non-ionic structure: Omniscan and OptiMARK

It can be noted that this classification was released after another proposition would have left the safest category (ionic cyclical structure) with only one agent (Dotarem, not sold in North America). The intermediate category would have been both ionic linear structure and non-ionic cyclical structure. The third category most at risk was unchanged (linear non-ionic).[10]

[edit] References

  1. ^ Scheinfeld, NS; Cowper, S; Kovarik, CL; Butler, DF. "Nephrogenic Fibrosing Dermatopathy." Emedicine. [1]
  2. ^ Cowper SE (2003). "Nephrogenic fibrosing dermopathy: the first 6 years". Current Opinion in Rheumatology 15 (6): 785–790. doi:10.1097/00002281-200311000-00017. PMID 14569211. 
  3. ^ Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE (2000). "Scleromyxoedema-like cutaneous diseases in renal-dialysis patients". Lancet 356 (9234): 1000–1. doi:10.1016/S0140-6736(00)02694-5. PMID 11041404. 
  4. ^ Mendoza FA, Artlett CM, Sandorfi N, Latinis K, Piera-Velazquez S, Jimenez SA (2006). "Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature". Semin. Arthritis Rheum. 35 (4): 238–49. doi:10.1016/j.semarthrit.2005.08.002. PMID 16461069. 
  5. ^ Grobner T (2006). "Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?". Nephrol. Dial. Transplant. 21 (4): 1104–8. doi:10.1093/ndt/gfk062. PMID 16431890. 
  6. ^ Marckmann P, Skov L, Rossen K, et al (2006). "Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging". J. Am. Soc. Nephrol. 17 (9): 2359–62. doi:10.1681/ASN.2006060601. PMID 16885403. 
  7. ^ Centers for Disease Control and Prevention (CDC) (2007). "Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents--St. Louis, Missouri, 2002-2006". MMWR Morb. Mortal. Wkly. Rep. 56 (7): 137–41. PMID 17318112. 
  8. ^ Kanal E, Barkovich AJ, Bell C, et al (2007). "ACR guidance document for safe MR practices: 2007". AJR. American journal of roentgenology 188 (6): 1447–74. doi:10.2214/AJR.06.1616. PMID 17515363. 
  9. ^ Medicines and Healthcare products Regulatory Agency. Drug Safety Update, August 2007 pg 2-4. Link (121 KB)
  10. ^ http://www.ismrm.org/special/EMEA2.pdf
Retrieved from "http://en.wikipedia.org/wiki/Nephrogenic_systemic_fibrosis"

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nephrogenic systemic fibrosis".

Find a Gadolinium & Nephrogenic System Fibrosis (NSF) Lawyer Now

This form is secure and encrypted. More information about secure forms and your privacy here.
* Required Fields

PERSONAL INFORMATION
First Name: *
Last Name: *
Address:
City:
State:
Zipcode:
Phone: -- ext.
Work Phone: -- ext.
E-mail Address: *

CASE INFORMATION
Have you been diagnosed with NSF (Nephrogenic Systemic Fibrosis) or NFD (Nephrogenic Fibrosing Dermopathy)? Yes No
When and where was the diagnosis made?
When did your problems start?

Describe your symptoms and how they developed.
Did you have an MRI (Magnetic Resonance Imaging) or MRA (Magnetic Resonance Angiography) scan done before your symptoms began? Yes No
Where and when was the scan (or scans, if more than one) done?
Did you have kidney failure, kidney function deficiency, or other kidney problems at the time the scan (or scans) were done? Yes No
Describe the kidney problems you had.

Need A Gadolinium & Nephrogenic Systemic Fibrosis (NSF) Attorney?

First Name Last Name Email Address State
Has Your Health Been Negatively Affected?

Please describe how you have been affected.

Your Friend's Email Address

Your Email Address

Type a Message (optional)


Looking for a Gadolinium & Nephrogenic Systemic Fibrosis (NSF) lawyer in District of Columbia? Get in touch with one of our Gadolinium & Nephrogenic Systemic Fibrosis (NSF) lawyers in District of Columbia now.

 

Close (x)

Looking for an Attorney?


Please type your question:

Close (x)

logo Find Legal Help for Your Gadolinium & Nephrogenic Systemic Fibrosis (NSF) Case - Submit Your Information Below

Do you need legal assistance with your Gadolinium & Nephrogenic Systemic Fibrosis (NSF) case?
LegalView may be able to help.


Submit your information below for a free, no-cost evaluation.

We'll submit your information to one of our partner firms.
LegalView's partners represent clients throughout the United States, for a very wide range of legal issues. Submit your information now, to see if one of LegalView's partners can help!
* Required Fields

PERSONAL INFORMATION
First Name: *
Last Name: *
Address:
City:
State:
Zipcode:
Phone: -- ext.
Work Phone: -- ext.
E-mail Address: *

CASE INFORMATION
Have you been diagnosed with NSF (Nephrogenic Systemic Fibrosis) or NFD (Nephrogenic Fibrosing Dermopathy)? Yes No
When and where was the diagnosis made?
When did your problems start?

Describe your symptoms and how they developed.
Did you have an MRI (Magnetic Resonance Imaging) or MRA (Magnetic Resonance Angiography) scan done before your symptoms began? Yes No
Where and when was the scan (or scans, if more than one) done?
Did you have kidney failure, kidney function deficiency, or other kidney problems at the time the scan (or scans) were done? Yes No
Describe the kidney problems you had.
This form is secure and encrypted. More information about secure forms and your privacy here.